Second tumors after oncologic treatment

Strahlentherapie und Onkologie

Volumn 184, Issue 2, 2008, Pages 67-72

  Dörr, Wolfgang ^a   Herrmann, Thomas ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Chemotherapy; Justifying indication; Radiotherapy; Second tumors

Indexed keywords

CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CANCER THERAPY; DATA COLLECTION METHOD; FOLLOW UP; IONIZING RADIATION; REVIEW; SURVIVAL RATE; TUMOR RECURRENCE;

HUMANS; INCIDENCE; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS;

EID: 38949106185     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-008-1807-5     Document Type: Review

References (30)

1. Birgisson H, Pahlman L, Gunnarsson U, et al. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005;23:6126-31.
2. Brenner DJ, Curtis RE, Hall EJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406.
3. Brenner H, Stegmaier C, Ziegler H. Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann Oncol 2005;16:981-6.
4. Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer 2007;43:351-62.
5. Clarke M, Collins R, Darby S, et al., Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
6. Coleman WB, Tsongalis GJ. Molecular mechanisms of human carcinogenesis. EXS 2006;96:321-49.
7. Dörr W, Hagen U, Eckardt-Schupp F. Strahlungen. In: Marquardt H, Schäfer SG, Hrsg. Lehrbuch der Toxikologie, 2. Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2004:1001-23.
8. Dörr W, Herrmann T. Second primary tumors after radiotherapy for malignancies. Treatment related parameters. Strahlenther Onkol 2002;178:2002:357-62.
9. Dörr W, Herrmann T. Cancer induction by radiotherapy: dose dependence and relation to irradiated volume. J Radiol Prot 2002;22:A117-21.
10. Dörr W, Stewart F. Retreatment tolerance of normal tissues. In: Van der Kogel AJ, Joiner MC, eds. Basic clinical radiobiology, 4th edn. London: Arnold, 2008: in preparation.
11. Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23:5644-50.
12. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003;56:1038-45.
13. Hashibe M, Ritz B, Le AD, et al. Radiotherapy for oral cancer as a risk factor for second primary cancers. Cancer Lett 2005;220:185-95.
14. Haussmann W. Carcinogenicity of cytostatic agents - secondary malignancy after chemotherapy. In: Rüther U, Nunnensiek C, Schmoll H-J, eds. Secondary neoplasms following chemotherapy, radiotherapy, and immunosuppression. Contributions to oncology, vol 55. Basel: Karger, 2000: 36-61.
15. Hawkins MM. Second primary tumors following radiotherapy for childhood cancer. Int J Radiat Oncol Biol Phys 1990;19:1297-301.
16. Hille A, Töws N, Schmidberger H, et al. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal tissue exposure. A potential for increasing the benefit/risk ratio. Strahlenther Onkol 2005;181:789-95.
17. Kleinerman RA, Boice JD Jr, Storm HH, et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 1995;76:442-52.
18. MacArthur AC, Spinelli JJ, Rogers PC, et al. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada. Pediatr Blood Cancer 2007;48:453-9.
19. Rades D, Schwarz R, Todorovic M, et al. Experiences with a new highdose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer. Strahlenther Onkol 2007;183:398-402.
20. Ruddon RW. Cancer biology, 4th edn. New York-Oxford: Oxford University Press, 2007.
21. Sanguineti G, Cavey ML, Endres EJ, et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy? Strahlenther Onkol 2006;182:543-9.
22. Schneider U, Lomax A, Pemler P, et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther Onkol 2006;182:647-52.
23. Soedirman JR. Secondary primary cancer after cancer and immunosuppressive chemotherapy and radiotherapy. In: Rüther U, Nunnensiek C, Schmoll H-J, eds. Secondary neoplasms following chemotherapy, radiotherapy, and immunosuppression. Contributions to oncology, vol 55. Basel: Karger, 2000:165-202.
24. Strahlenschutz in der Medizin. Richtlinie nach der Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung - StrlSchV) vom 22. April 2002. Berlin: Bundesministerium für Umwelt, Naturschutz und Reaktorsicherheit, 2002.
25. Strahlenschutzverordnung - StrlSchV. Verordnung über den Schutz vor Schäden durch ionisierende Strahlen vom 20. Juli 2001 (BGBl. I S. 1714, [2002, 1459]), zuletzt geändert durch Artikel 2 § 3 Abs. 31 des Gesetzes vom 1. September 2005 (BGBl. I S. 2618).
26. Suit H, Goldberg S, Niemierko A, et al. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects [Erratum in: Radiat Res 2007;167:748]. Radiat Res 2007;167:12-42.
27. Trott KR, Kamprad F. Estimation of cancer risks from radiotherapy of benign diseases. Strahlenther Onkol 2006;182:431-6.
28. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318:76-81.
29. Witherspoon RP, Deeg HJ, Fisher L, et al. Secondary malignancies after allogeneic or autologous marrow transplantation. In: Rüther U, Nunnensiek C, Schmoll H-J, eds. Secondary neoplasms following chemotherapy, radiotherapy, and immunosuppression. Contributions to oncology, vol 55. Basel: Karger, 2000:203-24.
30. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989;321:784-9.